ÂÜÀòÂÒÂ×

Steve has worked in oncology since 1999 and has experience in a wide range of areas, including medical affairs, product development, sales, marketing, and general management. He has a proven track record of success, with his last three of four companies all with investor exits of minimum 12x+ returns. He founded the multi-armed immunotherapy company, OncoMyx, in 2018 and raised $75M of venture funding. Previously, he was Vice President of Medical Affairs at Ignyta, which was recently acquired by Roche/Genentech for $1.7B, and he led the global operation of the testing of 20,000 patients in an oncology basket trial for entrectinib in 15 countries. The ROS1 & TRK kinase inhibitor, now launched by Roche (www.rozlytrek.com), was the first in the industry to receive breakthrough designation equivalents in USA, Europe, and Japan, and also one of the first to run a global concurrent registrational adult and pediatric trial.